Targeted Therapeutics Market Size, Share, Trends, Growth, Export Value, Volume & Trade, Sales, Pricing Forecast

Targeted therapies are drugs or other substances that block the growth of unwanted cells and pathogens by interfering with specific molecules ("molecular targets") involved in the growth, progression, and spread of disease. Targeted therapies are sometimes called molecularly targeted drugs, molecularly targeted therapies, precision medicines, etc. The emerging field of target therapeutics offers varied potential treatments. Target therapies involves a wide range of therapies, such as, gene therapy, which uses genetic material to alter cells (either in vivo or in vitro) to help cure disease , and stem cell therapy, that can be obtained from a very initial stage in human development and has the prospect to develop all the cell types in the human body. Targeted therapies offer the possibility of finding a cure for diseases with significant unmet needs, including orphan diseases and diseases having a high burden globally.

Rise in the number of newly diagnosed patients, rigorous research & development activities, adverse side effects of conventional therapies, and a rise in public awareness toward chronic illnesses across the world are the major factors driving the growth of the global targeted therapeutics market. Additionally, favorable reimbursement policies available in developed countries are projected to boost the growth of the targeted therapeutics market. However, high cost of the treatment, lack of favorable reimbursement schemes in developing economies, unavailability of the treatment in the Asian and African countries, such as, Thailand and the Philippines, and a shortage of skilled professionals are likely to restrain the growth of the targeted therapeutics market during the forecast period. Nevertheless, there are a number of late-stage pipeline candidates that are expected to generate strong annual revenue during the forecast period; for example, PD-1 inhibitor durvalumab for bladder cancer, head and neck cancer, liver cancer, renal cell carcinoma and the CDK-4 and -6 inhibitor abemaciclib for glioblastoma, liposarcoma, and mantle-cell lymphoma. Newer CAR-T cell therapies, Tisagenlecleucel-T and KTE-C19, are also expected to make an entry into the market and generate blockbuster revenues.

The global targeted therapeutics market can be segmented based on drug type, application type, distribution channel, and region. In terms of drug type, the targeted therapeutics market can be divided into monoclonal antibody therapeutics, protein/peptide therapeutics, small molecule drugs, RNA interference, stem cell therapy, and gene therapy. The monoclonal antibodies segment is likely to hold the leading share of the market during the forecast period; there are currently 73 monoclonal antibodies (mAb) approved for various indications with the purpose of extending the patient’s lifespan. The current market leader is Humira, which generated revenue of US$ 18.4 Bn in 2017 across a number of indications. Based on application, the market can be classified into immunology, oncology, infectious diseases, and others. Oncology is projected to be the leading segment of the market, in terms of market share, during the forecast period due to the high prevalence of the disorder and high level of use of immunotherapies in treatment regimes. Pharmaceutical companies worldwide are focused on developing target therapies to combat cancer at all stages and also for the treatment of the disease. In terms of the distribution channel, the market can be categorized into drug stores, retail pharmacies, hospital pharmacies, and online sales.

Geographically, the global targeted therapeutics market can be segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2016. Usage of targeted therapies is high in North America primarily due to steady approval for new indications and research undertakings and increasing geriatric population in the region. According to the Immune Deficiency Foundation, currently around 55,000 people in the U.S. with antibody deficiency receive primary immunodeficiency diseases treatment. Expected launch of targeted therapies in immunology and oncology that are presently in clinical trials in the U.S. is likely to boost the market growth in the region. Europe is expected to be the second-leading market for targeted therapeutics during the forecast period. Growth of the market in the region can be attributed to availability of several biologic drugs, such as, Rituxan, Humira, Enbrel, and others. The targeted therapeutics market in Asia Pacific is expected to register significant growth during the forecast period due to development of health care infrastructure, high disposable income of people, rise in health and hygiene-related awareness, large untapped market base, and economic development in the region.

Key players operating in the global targeted therapeutics market include Novartis AG, Amgen, Inc., Pfizer, Inc., GlaxoSmithKline plc., Merck & co., Sanofi, and Bristol-Myers Squibb Company. Several companies are developing targeted therapeutics. These include diversified companies developing targeted therapeutics as a part of their broad product portfolio, to highly specialized companies, focusing exclusively or near-exclusively on target therapeutics development.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

• Market segments and sub-segments
• Market trends and dynamics
• Supply and demand
• Market size
• Current trends/opportunities/challenges
• Competitive landscape
• Technological breakthroughs
• Value chain and stakeholder analysis

The regional analysis covers:

• North America (U.S. and Canada)
• Latin America (Mexico, Brazil, Peru, Chile, and others)
• Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
• Eastern Europe (Poland and Russia)
• Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
• Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

• A complete backdrop analysis, which includes an assessment of the parent market
• Important changes in market dynamics
• Market segmentation up to the second or third level
• Historical, current, and projected size of the market from the standpoint of both value and volume
• Reporting and evaluation of recent industry developments
• Market shares and strategies of key players
• Emerging niche segments and regional markets
• An objective assessment of the trajectory of the market
• Recommendations to companies for strengthening their foothold in the market   

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.